ReviewPLoS pathogens2021
Influenza viruses and coronaviruses: Knowns, unknowns, and common research challenges.
Review in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Serum lipidome remodeling in viral pneumonia: from pathophysiology to therapeutics.Frontiers in immunology · 2026Review
- Interferon-stimulated gene GALNT2 restricts respiratory virus infections.Nature microbiology · 2026Article
- Single cell transcriptomics correlate avian coronavirus prime vaccination efficacy with antigen-presenting cell preference.NPJ vaccines · 2025Article
- Antiviral potential of Melissa officinalis extracts against influenza and emerging coronaviruses.Scientific reports · 2025Article
- Research trends and hotspots on global influenza and inflammatory response based on bibliometrics.Virology journal · 2024Review
- Breaking the Chain: Protease Inhibitors as Game Changers in Respiratory Viruses Management.International journal of molecular sciences · 2024Review
- The Screening and Mechanism of Influenza-Virus Sensitive MDCK Cell Lines for Influenza Vaccine Production.Diseases (Basel, Switzerland) · 2024Article
- A research and development (R&D) roadmap for broadly protective coronavirus vaccines: A pandemic preparedness strategy.Vaccine · 2023Review
- Taxonomic Changes for Human Viruses, 2020 to 2022.Journal of clinical microbiology · 2023Review
- Rapid, label-free and low-cost diagnostic kit for COVID-19 based on liquid crystals and machine learning.Biosensors & bioelectronics: X · 2022Article
- TREX (transcription/export)-NP complex exerts a dual effect on regulating polymerase activity and replication of influenza A virus.PLoS pathogens · 2022Article
- Diagnostic and therapeutic approach to occupational pneumonia.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2022Review
- Inhibition of Respiratory RNA Viruses by a Composition of Ionophoric Polyphenols with Metal Ions.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Analysis of Interaction Network Between Host Protein and M Protein of Swine Acute Diarrhea Syndrome Coronavirus.Frontiers in microbiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of safe and effective vaccines in a record time after the emergence of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a remarkable achievement, partly based on the experience gained from multiple viral outbreaks in the past decades. However, the Coronavirus Disease 2019 (COVID-19) crisis also revealed weaknesses in the global pandemic response and large gaps that remain in our knowledge of the biology of coronaviruses (CoVs) and influenza viruses, the 2 major respiratory viruses with pandemic potential. Here, we review current knowns and unknowns of influenza viruses and CoVs, and we highlight common research challenges they pose in 3 areas: the mechanisms of viral emergence and adaptation to humans, the physiological and molecular determinants of disease severity, and the development of control strategies. We outline multidisciplinary approaches and technological innovations that need to be harnessed in order to improve preparedeness to the next pandemic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.